Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Reminder: Invitation to Roche's virtual analyst event during ESMO IO

12/03/2021 | 05:12am EST
Investor Update Reminder: Invitation to Roche's virtual analyst event during ESMO IO


We are pleased to invite investors and analysts to participate in our virtual event on Friday, 10 December 2021, highlighting new data from the tiragolumab Phase 2 Cityscape study including milestone overall survival data after 2.5 years of follow-up. The data will be presented at the congress scientific program, from Dec 8 - 11 2021.

16:00 - 16:50 CET / 15:00 - 15:50 GMT
10:00 - 10:50 am EST / 7:00 - 7:50 am PST

The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:00 CET on the day of the event. > click here

Agenda:

Welcome
Karl Mahler, Head of Investor Relations

CITYSCAPE updated analysis: Tiragolumab + Tecentriq in 1L NSCLC
Raymond Meng, M.D., Ph.D. - Global Development Leader Tiragolumab

Tiragolumab development overview
Heather Stevens, MBA, MPH - Life Cycle Leader, Tiragolumab

Q&A

Access to virtual event (pre-registration required)
Please pre-register for our webinar here*.

Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.

A replay of the webcast will be available via > ir.roche.com

*privacy notice

Best regards,

Karl Mahler
Head of Investor Relations



Sabine Borngräber
Investor Relations Officer

Roche Investor Relations
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com

Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com
Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com

Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com

Disclaimer

Roche Holding AG published this content on 03 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 December 2021 10:11:04 UTC.


ę Publicnow 2021
All news about ROCHE HOLDING AG
05:01aGMP production of CG01 made available for preclinical studies planned to enable First i..
AQ
01/13ROCHE HOLDINGS AG : JP Morgan gives a Neutral rating
MD
01/12Biogen shares slide as Medicare proposal restricts coverage of Alzheimer's treatments
RE
01/12Oncolytics Biotech Releases a Letter to Shareholders - 2021 Review and 2022 Outlook
AQ
01/12Roche launches the cobas« pulse system, an industry first professional blood glucose ma..
AQ
01/12Roche Launches Cobas Pulse System
CI
01/11U.S. Medicare plans to cover Biogen Alzheimer's drug only for trial patients
RE
01/11Sarepta Therapeutics' Gene Therapy SRP-9001 Shows Statistically Significant Functional ..
AQ
01/11SyroSyros Announces Clinical Updates and 2022 Goals to Support its Advancement to a Ful..
AQ
01/11ROCHE HOLDINGS AG : Deutsche Bank reiterates its Buy rating
MD
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2021 62 383 M 68 306 M 68 306 M
Net income 2021 15 276 M 16 727 M 16 727 M
Net Debt 2021 6 241 M 6 834 M 6 834 M
P/E ratio 2021 19,9x
Yield 2021 2,72%
Capitalization 296 B 324 B 324 B
EV / Sales 2021 4,84x
EV / Sales 2022 4,78x
Nbr of Employees 101 465
Free-Float -
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 365,00 CHF
Average target price 403,88 CHF
Spread / Average Target 10,7%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Pascale Schmidt Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-3.72%323 901
JOHNSON & JOHNSON-1.89%441 855
PFIZER, INC.-6.94%308 427
ABBVIE INC.0.35%240 202
ELI LILLY AND COMPANY-11.62%221 317
NOVO NORDISK A/S-15.01%218 444